Pomegra
Now I have the full picture. Writing the article now.
- Kimba secured $6.5M across a $1.1M pre-seed and a $5.4M seed round led by Selva Ventures, with participation from Resolute Ventures, Able Partners, and six other funds.
- The $299 device syncs with major smartwatches — including Apple Watch, Oura, WHOOP, and Garmin — to release water-based, plant-derived scent pulses calibrated to real-time sleep stage data.
- A 50-participant double-blind clinical study conducted over 48 nights showed 86% of users reported improved sleep quality and a 21% gain in cognitive performance.
Israeli sleeptech startup Kimba has closed a $6.5M seed round led by Selva Ventures to commercialize an AI-powered bedside diffuser that delivers personalized scent pulses to improve sleep quality.
Lead
Tel Aviv-based Kimba announced on June 15, 2026, the close of a $6.5 million funding round — $1.1 million in pre-seed capital followed by a $5.4 million seed led by Selva Ventures — to bring its AI-driven olfactory sleep technology to market in the United States. The company, founded by Israeli combat veteran Ben Fuxbruner and CTO Gabi Beck, is entering an estimated $80 billion global sleep-aid industry dominated by pharmaceuticals and hardware-heavy devices. Pre-orders for the device are now live at $299.What Happened
Fuxbruner, a mechanical engineer and former soldier in the Israel Defense Forces' elite Oketz canine unit, sustained severe injuries during combat operations in Gaza in 2014. The trauma left him with chronic PTSD and insomnia. His military service dog, named Kimba, died from wounds sustained in the same engagement — a loss that gave the company its name and its founding purpose.
The Kimba device sits on a bedside table and connects to a user's existing wearable — Apple Watch, Oura Ring, WHOOP, Fitbit, or Garmin — drawing on heart rate, breathing rate, movement, and inferred sleep stage to determine when and how much scent to release. The system delivers brief scent pulses from proprietary, plant-derived formulations, preventing the nasal habituation that typically blunts aromatherapy effects within minutes. Users complete an onboarding sleep profile and select from curated scent formulations tuned to their patterns; quarterly subscription refills are available after the initial six-month supply included in the device price.
Scientific Foundation
The approach exploits a well-established quirk of human neurobiology. Unlike sight and sound, which route through the thalamus before reaching the cortex, olfactory signals travel a direct pathway from the olfactory bulb into the limbic system — the brain structures governing emotion, memory, and autonomic regulation — and this pathway remains active during sleep. Kimba's clinical work is anchored by two academic collaborations: a completed double-blind trial led by Dr. Anat Arzi of Hebrew University's olfactory neuroscience and sleep lab, and an ongoing polysomnography study led by Prof. Peretz Lavie, a former president of the Technion and a leading authority on sleep medicine.
The double-blind study enrolled 50 participants over 48 nights. Across the cohort, 86% reported meaningful improvement in sleep quality, and cognitive performance scores — measured the morning after sleep sessions — rose by an average of 21%. A separate clinical track is examining Kimba's potential applications in PTSD-related sleep disruption, a direct extension of Fuxbruner's personal history.
Market Context
The sleeptech sector has attracted sustained investor interest as non-pharmaceutical interventions gain ground among consumers wary of dependency risks associated with prescription sedatives. Hardware-first products such as CPAP machines address specific clinical conditions but carry compliance challenges; consumer wearables have improved sleep tracking without meaningfully treating fragmented sleep. Kimba positions itself in the gap: a non-invasive, non-pharmaceutical device that acts on sleep rather than merely monitoring it.
The seed round's investor roster — Selva Ventures alongside Resolute Ventures, Able Partners, Barrel Ventures, Palette Ventures, Supermoon Capital, Air Ventures, Beyond 22, and Fresh Fund, the company's earliest backer — reflects broad cross-sector conviction spanning consumer health, wellness, and deep-tech. The company employs approximately ten people, primarily in Israel, and will use the capital to expand commercial operations in the United States.
Outlook
Kimba's near-term priorities are U.S. market penetration and completion of its PSG-based clinical trial, results from which would materially strengthen its evidence base ahead of any regulatory pathway or enterprise health-plan discussions. A launch in Israel is planned to follow the U.S. rollout. If polysomnography data confirms the self-reported outcomes from the double-blind study, the company will be positioned to move beyond the consumer wellness market toward clinical and insurance channels — a transition that would significantly expand addressable revenue and validate sleeptech as a therapeutic category.
Technology }}
